Unilateral osteoarthritis resulting from hip dysplasia, right hip
Methodology & AI Transparency ⓘ
Unilateral osteoarthritis resulting from hip dysplasia, right hip Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Under Osteoarthritis, Gout & Joint Pain diagnostic criteria (M16.31), workup for Unilateral osteoarthritis resulting from hip dysplasia, right hip integrates weight-bearing joint radiography [Unilateral osteoarthritis resulting from hip dysplasia, right hip M16.31] with evidence-graded therapy tailored to Weight-Bearing Joint Radiograph [Unilateral osteoarthritis resulting from hip dysplasia, right hip M16.31] response.
- 2 Real-world patient consensus: Mapped to Osteoarthritis, Gout & Joint Pain under ICD-10-CM M16.31 for Unilateral osteoarthritis resulting from hip dysplasia, right hip clinical workups.
- 3 Typical cash cost range: Clinicians assessing Unilateral osteoarthritis resulting from hip dysplasia, right hip focus on subchondral bone remodeling [Unilateral osteoarthritis resulting from hip dysplasia, right hip M16.31] and targeted history.
- 4 Top reported side effects / signs: Key Arthritis & Joints biomarkers for Unilateral osteoarthritis resulting from hip dysplasia, right hip (M16.31): Weight-Bearing Joint Radiograph [Unilateral osteoarthritis resulting from hip dysplasia, right hip M16.31] & Serum Uric Acid in Unilateral osteoarthritis resulting from hip dysplasia, right hip (M16.31: (Gout Target)) (< 6.0 mg/dL (< 5.0 mg/dL with tophi) (M16.31)).
Ask our AI Specialists anything about Unilateral osteoarthritis resulting from hip dysplasia, right hip
What Is Unilateral osteoarthritis resulting from hip dysplasia, right hip?
Under Osteoarthritis, Gout & Joint Pain diagnostic criteria (M16.31), workup for Unilateral osteoarthritis resulting from hip dysplasia, right hip integrates weight-bearing joint radiography [Unilateral osteoarthritis resulting from hip dysplasia, right hip M16.31] with evidence-graded therapy tailored to Weight-Bearing Joint Radiograph [Unilateral osteoarthritis resulting from hip dysplasia, right hip M16.31] response.
Pathophysiology, Underlying Causes & Clinical Presentation
Unilateral osteoarthritis resulting from hip dysplasia, right hip (M16.31) alters arthritis & joints homeostasis through subchondral bone remodeling [Unilateral osteoarthritis resulting from hip dysplasia, right hip M16.31]; clinical remission targets Serum Uric Acid in Unilateral osteoarthritis resulting from hip dysplasia, right hip (M16.31: (Gout Target)) within < 6.0 mg/dL (< 5.0 mg/dL with tophi) (M16.31).
Common Symptoms & Clinical Signs
- • Presentation of Unilateral osteoarthritis resulting from hip dysplasia, right hip (M16.31): sudden, intensely painful, in Unilateral osteoarthritis resulting from hip dysplasia, right hip (M16.31: red swollen big-toe)
- • Secondary Unilateral osteoarthritis resulting from hip dysplasia, right hip clinical sign: localized tendon or in Unilateral osteoarthritis resulting from hip dysplasia, right hip (M16.31: bursa tenderness limiting)
- • Symptom flares in Unilateral osteoarthritis resulting from hip dysplasia, right hip correlating with Weight-Bearing Joint Radiograph [Unilateral osteoarthritis resulting from hip dysplasia, right hip M16.31] deviation outside Preserved joint-space width (M16.31)
- • Functional arthritis & joints impact requiring weight-bearing joint radiography [Unilateral osteoarthritis resulting from hip dysplasia, right hip M16.31] evaluation (M16.31)
Unilateral osteoarthritis resulting from hip dysplasia, right hip Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | M16.31 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Osteoarthritis, Gout & Joint Pain | NLM Clinical Tables |
| Diagnostic / Lab Marker: Weight-Bearing Joint Radiograph [Unilateral osteoarthritis resulting from hip dysplasia, right hip M16.31] | Preserved joint-space width (M16.31) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Serum Uric Acid in Unilateral osteoarthritis resulting from hip dysplasia, right hip (M16.31: (Gout Target)) | < 6.0 mg/dL (< 5.0 mg/dL with tophi) (M16.31) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: hs-CRP & Erythrocyte in Unilateral osteoarthritis resulting from hip dysplasia, right hip (M16.31: Sedimentation Rate) | hs-CRP < 1.5 mg/L; ESR < 15 mm/hr (M16.31) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Unilateral osteoarthritis resulting from hip dysplasia, right hip
Treatment selection for Unilateral osteoarthritis resulting from hip dysplasia, right hip depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Unilateral osteoarthritis resulting from hip dysplasia, right hip)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Benefits and safety of risankizumab for active psoriatic arthritis: 24-week: What a 964-Participant Study Found Risankizumab treatment results in significantly greater improvement of signs and symptoms of PsA compared with placebo and is well tolerated in patients with active PsA who have responded inadequately or are intolerant to ≥1... Annals of the rheumatic diseases • 2022-02-15 • Phase III Randomized Trial | N = 964 | 93/100 | PMID 34911706 ↗ |
| New Insights on A single intra-articular injection of JTA-004, a combination of human plasma,: What a 746-Participant Study Found A single IA injection of JTA-004 was not superior to a saline solution (LSmean difference: -1.50 mm, 95%CI 5.12; 2.12, p= 0.42) or Synvisc-One® (LSmean difference: 2.40, 95% CI: -1.22; 6.02, p=0.20) for the treatment of OA... Osteoarthritis and cartilage • 2026-02-15 • Phase III Randomized Trial | N = 746 | 93/100 | PMID 41015076 ↗ |
| Can This Approach Help? Inside the Latest Research on VoiceS: voice quality after transoral CO 2 laser surgery versus single vocal cord Registered on 15 August 2019. Trials • 2022-10-27 • Phase III Randomized Trial | N = 34 | 82/100 | PMID 36303192 ↗ |
| Can This Approach Help? Inside the Latest Research on Long-Term Follow-Up After Unilateral Intravitreal Gene Therapy for Leber The treatment effect of lenadogene nolparvovec on BCVA and vision-related quality of life observed 96 weeks (2 years) after treatment in RESCUE and REVERSE was sustained at 3 years in RESTORE, with a maximum follow-up of 52. Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society • 2021-09-01 • Phase III Randomized Trial | N = 76 | 82/100 | PMID 34415265 ↗ |
| Can This Approach Help? Inside the Latest Research on Radiographic and clinical effects of 10 mg and 25 mg twice-weekly etanercept over The 25 mg BIW etanercept dosage does not appear to be significantly more efficacious than 10 mg in Japanese patients with RA. Modern rheumatology • 2021-03-15 • Phase III Randomized Trial | N = 182 | 82/100 | PMID 32735145 ↗ |
Unilateral osteoarthritis resulting from hip dysplasia, right hip Patient Community & “People Like Me” Threads
Filter Unilateral osteoarthritis resulting from hip dysplasia, right hip community threads and patient logs by age, biological sex, dosage, and treatment duration.